Publications
Detailed Information
Cost of treatment for multidrug-resistant tuberculosis in South Korea
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kang, Young Ae | - |
dc.contributor.author | Choi, Yong-Jun | - |
dc.contributor.author | Cho, Young-Jae | - |
dc.contributor.author | Lee, Sang Min | - |
dc.contributor.author | Yoo, Chul-Gyu | - |
dc.contributor.author | Kim, Young Whan | - |
dc.contributor.author | Han, Sung Koo | - |
dc.contributor.author | Shim, Young-Soo | - |
dc.contributor.author | Yim, Jae-Joon | - |
dc.date.accessioned | 2010-01-07T01:33:18Z | - |
dc.date.available | 2010-01-07T01:33:18Z | - |
dc.date.issued | 2006-10-21 | - |
dc.identifier.citation | Respirology. 2006 Nov;11(6):793-8. | en |
dc.identifier.issn | 1323-7799 (Print) | - |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17052310 | - |
dc.identifier.uri | https://hdl.handle.net/10371/27661 | - |
dc.description.abstract | OBJECTIVE AND BACKGROUND: Costs associated with multidrug-resistant tuberculosis (MDR-TB) are higher than those associated with drug-susceptible TB because of the higher prices of second-line anti-TB drugs, the prolonged duration of treatment, greater productivity loss and higher mortality. The aim of this study was to estimate the cost of treatment for MDR-TB according to the treatment strategy and prognosis in South Korea. METHODS: We estimated the direct (medical and non-medical) and indirect cost for the treatment of MDR-TB according to the treatment strategies and prognosis: in medically treated, surgically treated and deceased patients groups. The same analyses were undertaken for drug-susceptible TB for comparison. The patients with MDR-TB or drug-susceptible TB were randomly selected from the TB cohort of Seoul National University Hospital, Seoul, South Korea. RESULTS: Direct costs per person were US$4000 (US$2527-4841) in the medically treated group, US$17,457 (US$10,133-26,418) in the surgically treated group and US$33,362 (US$25 386-40 338) in the deceased group. Total costs per person were US$15,856 (US$10,752-38,421), US$47,159 (US$20,587-77,622) and US$478,357 (US$257,377-777,778), respectively. For the patients with drug-susceptible TB, the total cost ranged from US$1680 to US$7637 (median US$2166). CONCLUSIONS: The cost for the treatment of MDR-TB is seven to 22 times that of managing the drug-susceptible TB in South Korea. Considering the high cost, transmissibility and considerable fatality of MDR-TB, there is a need to provide specific separate funding for multidrug-resistant tuberculosis. | en |
dc.language.iso | en | en |
dc.publisher | Wiley-Blackwell | en |
dc.subject | Adult | en |
dc.subject | Efficiency, Organizational/economics | en |
dc.subject | Female | en |
dc.subject | Health Care Costs/*statistics & numerical data | en |
dc.subject | Humans | en |
dc.subject | Korea/epidemiology | en |
dc.subject | Male | en |
dc.subject | Middle Aged | en |
dc.subject | Prevalence | en |
dc.subject | Time Factors | en |
dc.subject | Tuberculosis, Multidrug-Resistant/*drug therapy/*economics/epidemiology | en |
dc.subject | Tuberculosis, Pulmonary/*drug therapy/*economics/epidemiology | en |
dc.title | Cost of treatment for multidrug-resistant tuberculosis in South Korea | en |
dc.type | Article | en |
dc.contributor.AlternativeAuthor | 강영애 | - |
dc.contributor.AlternativeAuthor | 최용준 | - |
dc.contributor.AlternativeAuthor | 조영재 | - |
dc.contributor.AlternativeAuthor | 이상민 | - |
dc.contributor.AlternativeAuthor | 유철규 | - |
dc.contributor.AlternativeAuthor | 김영환 | - |
dc.contributor.AlternativeAuthor | 한성구 | - |
dc.contributor.AlternativeAuthor | 심영수 | - |
dc.contributor.AlternativeAuthor | 임재준 | - |
dc.identifier.doi | 10.1111/j.1440-1843.2006.00948.x | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.